Achaogen Stock

Achaogen Equity Ratio

Delisted

The Equity Ratio of Achaogen (AKAOQ) as of Aug 16, 2026 is -7.64 %. In the previous year, Equity Ratio was 61.89 % — a change of -112.35% (lower).

Equity Ratio

-7.64 %

YoY

-112.35%

Last updated:

Equity Ratio of Achaogen is 2026 -7.64 % . Equity Ratio of Achaogen was 2025 61.89 % . It decreases by -112.35% lower compared to the previous year.
Access this data via the Eulerpool API

Achaogen Stock analysis

What does Achaogen do? Achaogen Inc is an innovative biotechnology company specializing in the development of antibiotics for the treatment of life-threatening infectious diseases. The company's business model is based on research and development of new antibiotics, aiming to improve medical care for patients with infections. Achaogen was founded in 2002 by a team of researchers and professionals in the biotechnology industry and has developed several products for the treatment of diseases such as pneumonia, urinary tract infections, and bloodstream infections. The company's main divisions include Plazomicin, Zemdri, and C-Scape, which are antibiotics targeting different types of infections. Achaogen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Achaogen stock

Equity Ratio of Achaogen is -7.64 % in 2026.

Equity Ratio of Achaogen changed from 61.89 % to -7.64 %, representing a -112.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Achaogen since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Achaogen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Achaogen

All Key Metrics — Achaogen